Alteon starts heart failure Phase IIa

ALT began a U.S. Phase IIa trial (PEDESTAL) of its alagebrium (formerly ALT-711) in 20 patients with diastolic dysfunction and impaired ejection fraction. The primary endpoints of the open-label trial...